KNG1 Protein (Transcript Variant 2) (Myc-DYKDDDDK Tag)
-
- Antigène Voir toutes KNG1 Protéines
- KNG1 (Kininogen 1 (KNG1))
- Type de proteíne
- Recombinant
- Attributs du protein
- Transcript Variant 2
-
Origine
- Humain
-
Source
- HEK-293 Cells
- Purification/Conjugué
- Cette KNG1 protéine est marqué à la Myc-DYKDDDDK Tag.
- Application
- Antibody Production (AbP), Standard (STD)
- Attributs du produit
-
- Recombinant human Kininogen-1 (transcript variant 2) protein expressed in HEK293 cells.
- Produced with end-sequenced ORF clone
- Pureté
- > 80 % as determined by SDS-PAGE and Coomassie blue staining
- Top Product
- Discover our top product KNG1 Protéine
-
-
- Indications d'application
-
Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays - Commentaires
-
The tag is located at the C-terminal.
- Restrictions
- For Research Use only
-
- Concentration
- 50 μg/mL
- Buffer
- 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
- Stock
- -80 °C
- Stockage commentaire
- Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.
-
- Antigène
- KNG1 (Kininogen 1 (KNG1))
- Autre désignation
- Kininogen-1 (KNG1 Produits)
- Synonymes
- BDK Protein, BK Protein, KNG Protein, Kng Protein, KNG2 Protein, fb64g01 Protein, wu:fb64g01 Protein, zgc:103569 Protein, kininogen Protein, bdk Protein, kng Protein, KNG1 Protein, IHRP Protein, KINKG Protein, KINKH Protein, Kng1 Protein, Kngk Protein, kininogen 1 Protein, kininogen 1 L homeolog Protein, inter-alpha-trypsin inhibitor heavy chain family member 4 Protein, kininogen 2-like 1 Protein, KNG1 Protein, Kng1 Protein, kng1 Protein, kng1.L Protein, ITIH4 Protein, Kng2l1 Protein
- Sujet
- (1) Kininogens are inhibitors of thiol proteases (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action) (5) LMW-kininogen inhibits the aggregation of thrombocytes (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. [UniProtKB/Swiss-Prot Function]
- Poids moléculaire
- 47.7 kDa
- NCBI Accession
- NP_000884
- Pathways
- ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process
-